(Q34097586)

31 July 2017

1 reference

title

Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside (English)

1 reference

31 July 2017

2

Robert Stuart

1 reference

31 July 2017

Munira Shabbir

1

1 reference

PubMed ID

20141349

31 July 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

1 reference

31 July 2017

19

1 reference

31 July 2017

3

1 reference

31 July 2017

427-436

1 reference

31 July 2017

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

K-252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003598862

K-252a, a potent inhibitor of protein kinase C from microbial origin

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.39.1059

Identifiers

DOI

10.1517/13543781003598862

1 reference

31 July 2017

1 reference

PubMed ID

20141349